Status:
COMPLETED
Pharmacogenomic Testing to Personalize Supportive Oncology
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Cancer
Depression
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate pharmacogenomics (PGx) guided drug prescribing for pain and depression in patients with cancer. The investigators aim to understand how PGx testing can be used...
Detailed Description
This is a prospective clinical trial of adult cancer patients presenting with pain and depression, newly referred to the Department of Supportive Oncology, and receiving preemptive PGx testing for gen...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Written informed consent and HIPAA authorization for release of personal health information.
- Completion of ESAS at initial palliative medicine clinic visit, presenting with moderate to high pain (≥ 4/10) and/or depression (≥ 3/10).
- New patients ≥ 18 years of age who have had an initial visit in the Department of Supportive Oncology's palliative medicine clinic with hematologic malignancy or any stage solid tumor malignancy according to the provider.
- Agree to at least one additional palliative medicine clinic visit per protocol.
- Able to provide a buccal sample for PGx testing.
- Exclusion Criteria
- Psychiatric illness, social situations, or active/recent (within 30 days) history of illicit substance (e.g. cocaine, heroin) abuse that would limit compliance with study requirements (e.g. clinic visits, medication compliance, etc.) as determined by the Investigator.
- Patients who have had prior multiple visits in palliative medicine clinic.
Exclusion
Key Trial Info
Start Date :
December 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 13 2023
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04500301
Start Date
December 2 2020
End Date
December 13 2023
Last Update
January 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204